| Date | Title | | | 06/21/10 | Ardea Biosciences to Present at the Fifth Annual Piper Jaffray Europe Conference| SAN DIEGO, June 21, 2010 /PRNewswire via COMTEX/ --Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, PharmD, president and chief executive officer, will present at the Fifth Annual Piper Jaffray Europe Conference in London, England. Dr. Quart is scheduled to present at 11:30 a.m. BST on Tuesday, June 22, 2010.
This presentation will be webcast and can be accessed on the Investor Relations section of Ardea's website at www.ardeabio.com. Please connect to Ardea's websi... |
|  | | 06/18/10 | Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate for the Treatment of Hyperuricemia and Gout, Presented at the Annual European Congress of Rheumatology| New Data from Five Clinical Studies Reinforce RDEA594's Robust Efficacy and Encouraging Safety Profile
ROME, June 18, 2010 /PRNewswire via COMTEX/ --Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that additional positive data from its Phase 2 program for RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy. RDEA594, a ... |
| | | 06/07/10 | Ardea Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference| SAN DIEGO, June 7, 2010 /PRNewswire via COMTEX/ --Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, PharmD, president and chief executive officer, will present at the Jefferies 2010 Global Life Sciences Conference in New York, New York. Dr. Quart is scheduled to present at 2:00 p.m. EDT on Tuesday, June 8, 2010.
This presentation will be webcast and can be accessed on the Investor Relations section of Ardea's website at http://www.ardeabio.com/. Please connect to Arde... |
| | | 05/14/10 | Ardea Biosciences to Present at Two Upcoming Investor Conferences| SAN DIEGO, May 14, 2010 /PRNewswire via COMTEX/ --Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, PharmD, president and chief executive officer, will present at the following upcoming investor conferences:
Brean Murray, Carret & Co. 2010 Life Sciences Summit in New York, New York. Presentation: 9:30 a.m. EDT on Monday, May 17, 2010.
Citi 2010 Healthcare Conference in New York, New York. Presentation: 1:30 p.m. EDT on Thursday, May 27, 2010. This presentatio... |
| | | 05/13/10 | Ardea Biosciences to Present Additional Data on Gout Program at the Annual European Congress of Rheumatology| SAN DIEGO, May 13, 2010 /PRNewswire via COMTEX/ --Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it will present additional data from its completed Phase 2a and Phase 2b monotherapy studies of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy on June 18th and 19th. The Company will also present additional RDEA594 and allopurinol comb... |
| | | 05/07/10 | Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2010 Financial Results| SAN DIEGO, May 7, 2010 /PRNewswire via COMTEX/ --Ardea Biosciences, Inc. (Nasdaq: RDEA) a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), today reported recent accomplishments and financial results for the first quarter ended March 31, 2010.
"We are pleased to have accomplished a number of very important objectives since our last quarterly update," commented Barry D. Quart, PharmD, preside... |
| | | 05/06/10 | Ardea Biosciences to Present at Two Upcoming Investor Conferences| SAN DIEGO, May 6, 2010 /PRNewswire via COMTEX/ --Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, PharmD, president and chief executive officer, will present at the following upcoming investor conferences:
9th Annual JMP Securities Research Conference in San Francisco, California. Presentation: 9:00 a.m. PDT on Monday, May 10, 2010.
Bank of America Merrill Lynch Healthcare Conference in New York, New York. Presentation: 8:40 a.m. EDT on Thursday, May 13, 2010. ... |
| | | 04/12/10 | Ardea Biosciences, Inc. Announces Appointment of Stephen R. Davis as Executive Vice President and Chief Operating Officer| SAN DIEGO, April 12, 2010 /PRNewswire via COMTEX/ --Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced the appointment of Stephen R. Davis as Executive Vice President and Chief Operating Officer.
"We are extremely pleased to welcome Steve to Ardea as our new Chief Operating Officer," commented Barry D. Quart, PharmD, Ardea's President and Chief Executive Officer. "His diverse background, with extensive financial and transactional experience, makes him an ideal addition to the Ardea managem... |
| | | 04/09/10 | Ardea Biosciences, Inc. Announces Completion of Public Offering of Common Stock| SAN DIEGO, April 9, 2010 /PRNewswire via COMTEX/ --Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced the completion of a public offering of 4,025,000 shares of its common stock, including 525,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. All of the shares were offered by Ardea Biosciences. The net proceeds to Ardea Biosciences from the sale of shares in the offering, after deducting underwriting discounts and commissions, we... |
| | | 04/06/10 | Ardea Biosciences, Inc. Announces Pricing of Public Offering of Common Stock| SAN DIEGO, April 6, 2010 /PRNewswire via COMTEX/ --Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced the pricing of a public offering of 3,500,000 shares of its common stock. The offering is expected to close on or about April 9, 2010, subject to customary closing conditions. In addition, Ardea Biosciences has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares to cover overallotments, if any.
Jefferies & Company, Inc. is acting as sole book-running... |
| | | 04/05/10 | Ardea Biosciences, Inc. Announces Proposed Public Offering of Common Stock| SAN DIEGO, April 5, 2010 /PRNewswire via COMTEX/ --Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager in this offering. The joint lead manager in this offering is Oppenheimer & Co. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual si... |
| | | 03/31/10 | Ardea Biosciences Announces Positive Top-Line Results from a Phase 2b Study of RDEA594 Given as Monotherapy in the Treatment of Hyperuricemia in Gout Patients| --RDEA594 Significantly Reduced Serum Urate Levels in Gout Patients and Was Well Tolerated --Conference Call and Webcast Scheduled for 5:00 P.M. Eastern Time Today
SAN DIEGO, March 31, 2010 /PRNewswire via COMTEX/ --Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-... |
| | | 03/12/10 | Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance| SAN DIEGO, March 12, 2010 /PRNewswire via COMTEX/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), today reported recent accomplishments, announced fourth quarter and full-year 2009 financial results and provided key upcoming clinical development milestones and financial guidance for 2010.
"Having already confirmed RDEA594's single-agent potential... |
| | | 03/05/10 | Ardea Biosciences to Present at Two Upcoming Investor Conferences| SAN DIEGO, March 5, 2010 /PRNewswire via COMTEX/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that the Company will present at the following investor conferences during the month of March 2010:
Cowen and Company 30th Annual Health Care Conference in Boston, Massachusetts. Barry D. Quart, Pharm.D., president and chief executive officer, will present at 1 p.m. EST on Monday, March 8, 2010. This presentation will be webcast and can be accessed on the Investor Center section... |
| | | 02/09/10 | Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors| SAN DIEGO, Feb 09, 2010 /PRNewswire via COMTEX/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that Felix J. Baker, Ph.D., has been appointed to the Company's Board of Directors. Dr. Baker is a managing partner of Baker Bros. Advisors, LLC, the manager and advisor to the funds of Baker Brothers Investments, Ardea's largest shareholder.
"Ardea's impressive accomplishments have made it an important company in our portfolio, so I am pleased to join the Board of Directors," commented Dr... |
| | | 02/05/10 | Ardea Biosciences to Present at the 12th Annual BIO CEO and Investor Conference| SAN DIEGO, Feb 05, 2010 /PRNewswire via COMTEX/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the 12th Annual BIO CEO and Investor Conference.
Presentation details are as follows:
Date: Tuesday, February 9, 2010
Time: 11:00 a.m. Eastern Time
Location: The Waldorf-Astoria Hotel, New York, NY
Webcast: http://www.veracast.com/webcasts/bio/ceoinvestor2010/13205183.cfm
About Ardea Bioscienc... |
| | | 01/07/10 | Ardea Biosciences Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination with Allopurinol or Febuxostat| - 100% of patients reached target serum urate levels with the combination of RDEA594 and allopurinol - RDEA594 combined with febuxostat reduced serum urate levels in healthy volunteers by approximately 70%SAN DIEGO, Jan 07, 2010 /PRNewswire via COMTEX/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced additional positive results from a recently completed Phase 2a study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, as well as additional positive resul... |
| |
|
